首页> 中文期刊>世界临床病例杂志 >Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients

Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients

     

摘要

BACKGROUND Supported by the National Natural Science Foundation of China,No.The prognostic value of coagulation disorder in coronavirus disease 2019(COVID-19)patients should be demonstrated.AIM To investigate the abnormalities of coagulation parameters in the patients with COVID-19 and their prognostic values.METHODS Consecutive patients admitted in the isolation ward of Renmin Hospital of Wuhan University from January 31 to February 5,2020 with confirmed COVID-19 were included.The primary outcomes were death and survival as of March 11.Demographics,vital signs,comorbidities and laboratory tests were collected and compared between those who died and survivors.Logistic regression analysis for prognostic factors was performed.Kaplan-Meier analysis was used to compare the estimated survival rate between patients with prolonged prothrombin time and normal prothrombin time.RESULTS The total number of patients with confirmed COVID-19 who were enrolled was 213.The median age was 62 years,and 95 patients(44.6%)were men.Fifty-one patients were critical(23.9%),79 patients were severe(37.1%)and 83 patients were moderate(39%).As of March 11,2020,99 patients were discharged(46.5%),79 patients(37.1%)stayed in the hospital and 35 patients(16.2%)died.Median time to death was 6(4-8)d,while median hospital stay was 32(22-36)d in survivors(P<0.001).More men(P=0.002)and elderly patients(P<0.001)were found in the group of those who died.The respiration rate at admission was higher in the group of those who died(P<0.001).The incidences of hypertension(P=0.028),cerebrovascular disease(P<0.001),chronic kidney disease(P=0.02)and chronic obstructive pulmonary disease(P<0.001)were higher in the group of those who died.Platelet count was decreased in the group of those who died(P=0.002)whereas prothrombin time(P<0.001),activated partial thromboplastin time(P=0.033),concentration of D-dimer(P<0.001)and fibrin degradation products(P<0.001)were increased in the group of those who died.Prothrombin time[odds ratio(OR):2.19,P=0.004],respiration rate(OR:1.223,P<0.001),age(OR:1.074,P<0.001)and fibrin degradation products concentration(OR:1.02,P=0.014)were predictors of death.The survival rate was significantly lower in patients with prolonge CONCLUSION Prothrombin time,concentration of fibrin degradation products,respiration rate and age were predictive factors for clinical outcomes of COVID-19 patients.

著录项

  • 来源
    《世界临床病例杂志》|2020年第19期|P.4370-4379|共10页
  • 作者单位

    Department of Cardiology Renmin Hospital of Wuhan University Wuhan 430060 Hubei Province ChinaCardiovascular Research Institute Wuhan University Wuhan 430060 Hubei Province ChinaHubei Key Laboratory of Cardiology Wuhan 430060 Hubei Province China;

    Department of Cardiology Renmin Hospital of Wuhan University Wuhan 430060 Hubei Province ChinaCardiovascular Research Institute Wuhan University Wuhan 430060 Hubei Province ChinaHubei Key Laboratory of Cardiology Wuhan 430060 Hubei Province China;

    Department of Cardiology Renmin Hospital of Wuhan University Wuhan 430060 Hubei Province ChinaCardiovascular Research Institute Wuhan University Wuhan 430060 Hubei Province ChinaHubei Key Laboratory of Cardiology Wuhan 430060 Hubei Province China;

    School of Biotechnology and Biomolecular Sciences The University of New South Wales Sydney 2052 Australia;

    Department of Cardiology Renmin Hospital of Wuhan University Wuhan 430060 Hubei Province ChinaCardiovascular Research Institute Wuhan University Wuhan 430060 Hubei Province ChinaHubei Key Laboratory of Cardiology Wuhan 430060 Hubei Province China;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 肿瘤学;
  • 关键词

    COVID-19; Coagulation; Prothrombin time; Fibrin degradation products; Prognosis; Infectious disease;

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号